Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

about

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

Item

http://www.wikidata.org/entity/Q51738217

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

@en

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

@nl

type

Item

label

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

@en

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

@nl

prefLabel

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

@en

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

@nl

P1476

Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA.

@en

P2093

Kieu-Nhi Tran

http://www.w3.org/2001/XMLSchema#string

Michael J Rybak

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus

Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model

Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.

Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.

Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus

Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherap

P31

scholarly article

P356

10.1128/AAC.00157-18

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2018-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29555635

http://www.w3.org/2001/XMLSchema#string

P932

5971571

http://www.w3.org/2001/XMLSchema#string